A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1568-1575

  Tebbutt, N C ^a   Norman, A ^a   Cunningham, D ^a   Iveson, T ^b   Seymour, M ^c   Hickish, T ^d   Harper, P ^e   Maisey, N ^a   Mochlinski, K ^a   Prior, Y ^a   Hill, M ^a,f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Southampton Hospital   (Germany)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

5 Fluorouracil; Mitomycin C; Oesophago gastric cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS CARCINOMA; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LETHARGY; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; STOMATITIS; SYMPTOMATOLOGY; TREATMENT FAILURE; TUMOR DIFFERENTIATION; WEIGHT REDUCTION; ESOPHAGUS TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PAIN; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; PAIN; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0036771724     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf273     Document Type: Article

References (24)

1. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
2. Preusser P, Achterrath W, Wilke H et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988; 15: 257-277.
3. Hill ME, Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev 1998; 24: 113-118.
4. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
5. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
6. Pye JK, Crumplin MK, Charles J et al. One-year survey of carcinoma of the oesophagus and stomach in Wales. Br J Surg 2001; 88: 278-285.
7. Repetto L, Venturino A, Vercelli M et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998; 82: 760-765.
8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-308.
9. Moynihan T, Hansen R, Anderson T et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461-464.
10. Louvet C, de Gramont A, Demuynck B et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2: 229-230.
11. Vanhoefer U, Wilke H, Weh HJ et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994; 5: 850-851.
12. Russello O, Romanini A, Civalleri D et al. Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 1989; 25: 571-572.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Macdonald JS, Haller D, Mayer RJ. Grading of Toxicity. Manual of Oncologic Therapeutics. Philadelphia, PA: Lippincott 1995; 519-523.
15. Ringdal GI, Ringdal K. Testing the EORTC Quality of life questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993; 2: 129-140.
16. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249-1254.
17. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001.
18. Maisey N, Chau I, Cunningham D et al. Multi-centre randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin-C (MMC) in inoperable pancreatic cancer. J Clin Oncol 2002; 20: 3130-3136.
19. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Star Assoc 1958; 53: 457-481.
20. Peto R, Peto J. Asymptotically efficient invariant procedures. J R Stat Soc 1972; 135: 185-206.
21. Cox D, Oakes D. Analysis of Survival Data. New York, NY: Chapman and Hall 1984.
22. Highley MS, Hill ME, Ziras N et al. High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma. Br J Cancer 1993; 67: 407-408.
23. Wils JA, Klein HO, Wagener DJ et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
24. Ross P, Nicolson M, Cunningham D et al. A prospective randomised trial comparing MCF with ECF in advanced oesophago-gastric cancer. J Clin Oncol 2002; 20: 1996-2004.